In the article “Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients” [Dermatology. 2021; doi 10.1159/000519924] by Drerup et al., the authors found that incorrect standard deviations were given for all measurements in Figure 1. The corrected Figure 1 is shown here.
Fig. 1.
Course of PASI (a), BSA (b), DLQI (c), and itch-VAS (d) in patients included into the KTC from baseline until week 76. Values are mean and standard deviation.